Edwards Lifesciences — Third Quarter 2026 Earnings Summary

Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, representing a 10.5% increase from the prior year, with adjusted earnings per share rising 19% to $0.80. The company's Transcatheter Mitral and Tricuspid Therapies segment saw significant growth of 44.0%, while Transcatheter Aortic Valve Replacement sales increased by 8.0%. Driven by strong performance across its product lines and regions, Edwards raised its full-year 2026 sales growth guidance to approximately 11.5% and adjusted EPS guidance to a range of $2.97 to $3.05.